Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 20/20 | 0.69 |
| ▸ | BMPR1A | P36894 | 9/20 | 0.69 |
| ▸ | ACVR1B | P36896 | 8/20 | 0.69 |
| ▸ | BMPR1B | O00238 | 7/20 | 0.69 |
| ▸ | ACVRL1 | P37023 | 7/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16112432 | 1.00 | ACVR1 (0.69) | ACVR1BMPR1AACVR1BBMPR1BACVRL1 | |
| SCHEMBL16111923 | 0.91 | ACVR1 (0.69) | ACVR1BMPR1AACVR1BBMPR1BACVRL1 | |
| SCHEMBL16111925 | 0.91 | ACVR1 (0.69) | ACVR1BMPR1AACVR1BBMPR1BACVRL1 | |
| SCHEMBL17509657 | 0.89 | ACVR1 (0.67) | ACVR1BMPR1AACVR1BBMPR1BACVRL1 | |
| SCHEMBL16134935 | 0.89 | ACVR1 (0.67) | ACVR1BMPR1AACVR1BBMPR1BACVRL1 | |
| SCHEMBL19611370 | 0.89 | ACVR1 (0.67) | ACVR1BMPR1AACVR1BBMPR1BACVRL1 | |
| SCHEMBL16112415 | 0.87 | ACVR1 (0.69) | ACVR1BMPR1AACVR1BBMPR1BACVRL1 | |
| SCHEMBL17442054 | 0.87 | ACVR1 (0.50) | ACVR1BMPR1AACVR1BBMPR1BACVRL1 | |
| SCHEMBL17442056 | 0.87 | ACVR1 (0.50) | ACVR1BMPR1AACVR1BBMPR1BACVRL1 | |
| SCHEMBL17509652 | 0.86 | ACVR1 (0.68) | ACVR1BMPR1AACVR1BBMPR1BACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017516-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9682983-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| EP-2970311-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | The Brigham and Women's Hospital, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160203-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | BMP1, BMPR2, BMP2 | ACVR1 13/4885BMPR1A 5/4885ACVR1B 16/4885 |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | BMP1, BMPR2, BMP2 | ACVR1 13/4885BMPR1A 5/4885ACVR1B 16/4885 |
| US-10017516-B2 | BMP inhibitors and methods of use thereof | BMP1, BMPR2, BMP2 | ACVR1 13/4885BMPR1A 5/4885ACVR1B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.